Effect of teriparatide treatment on endothelial function, glucose metabolism and inflammation markers in patients with postmenopausal osteoporosis

Çeler, Özgen; Akalın, Ayşen; Öztunalı, Çiğdem

doi:10.1111/cen.13139

Cited by 15 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, high bone turnover or anabolic agents that lead to release of bone matrix–derived SOST or DKK1 could potentially have unfavorable cardio–metabolic effects. Indeed, intermittent teriparatide treatment has been shown to adversely affect glucose metabolism, inflammation, and endothelial function [48]. Obviously, this is conjecture, and it is unknown if bone matrix–derived DKK1 or SOST is functional and a significant source of systemic levels.…”

Section: Discussionmentioning

confidence: 99%

Bone Matrix Levels of Dickkopf and Sclerostin are Positively Correlated with Bone Mass and Strength in Postmenopausal Osteoporosis

Ueland

Stilgren

Bollerslev

2019

IJMS

View full text Add to dashboard Cite

Wnt signaling plays a pivotal role in maintaining bone mass. Secreted pathway modulators such as sclerostin (SOST) and Dickkopfs (DKKs) may influence bone mass inhibiting the canonical Wnt pathway. We evaluated whether bone protein content of secreted Wnt antagonists is related to age, bone mass, and strength in postmenopausal osteoporosis. We measured cortical and trabecular bone contents of SOST and Dickkopf-1 (DKK1) in combined extracts obtained after ethylenediaminetetraacetic acid and guanidine hydrochloride extraction in 56 postmenopausal women aged 47–74 (mean, 63) yr with a previous distal forearm fracture and a hip or spine Z-score less than 0. Our findings were (i) SOST and DKK1 protein levels were higher in trabecular bone, (ii) cortical and trabecular DKK1 and trabecular SOST correlated positively with bone matrix levels of osteocalcin (r between 0.28 and 0.45, p < 0.05), (iii) cortical DKK1 correlated with lumbar spine bone mineral density (BMD) (r = 0.32, p < 0.05) and femoral neck BMD (r = 0.41, p < 0.01), and (iv) cortical DKK1 and SOST correlated with apparent bone volumetric density and compressive strength (r between 0.34 and 0.51, p < 0.01). In conclusion, cortical bone matrix levels of DKK1 and SOST were positively correlated with bone mass and bone strength in postmenopausal osteoporotic women.

show abstract

Section: Discussionmentioning

confidence: 99%

Bone Matrix Levels of Dickkopf and Sclerostin are Positively Correlated with Bone Mass and Strength in Postmenopausal Osteoporosis

Ueland

Stilgren

Bollerslev

2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Conclusions from clinical trials regarding the action of teriparatide on carbohydrate management parameters are often contradictory, and the effect on glucose homeostasis remains unknown, although the role of calcium and its effect on glucose transport to the cell and the regulation of insulin receptors are postulated [ 107 ]. Celer et al showed that the use of teriparatide in patients with postmenopausal osteoporosis increased glucose concentrations, whereas Anastasilakis et al showed that this trend decreases when teriparatide treatment is continued [ 108 , 109 ]. In summary, there are no randomized trials using these therapies in patients with type 1 diabetes in terms of anabolic osteoporosis therapies.…”

Section: Anti-osteoporosis Drugs and Glucose Metabolismmentioning

confidence: 99%

Treatment of Diabetes and Osteoporosis—A Reciprocal Risk?

et al. 2022

View full text Add to dashboard Cite

Diabetes mellitus is a metabolic and systematic disorder that requires individualized therapy. The disease leads to various consequences, resulting in the destruction of tissues and organs. The aforementioned outcomes also include bone mineral disorders, caused by medications as well as diet therapy and physical activity. Some drugs may have a beneficial effect on both bone mineral density and the risk of fractures. Nevertheless, the impact of other medications remains unknown. Focusing on pharmacotherapy in diabetes may prevent bone mineral disorders and influence both the treatment and quality of life in patients suffering from diabetes mellitus. On the other hand, anti-osteoporosis drugs, such as antiresorptive or anabolic drugs, as well as drugs with a mixed mechanism of action, may affect carbohydrate metabolism, particularly in patients with diabetes. Therefore, the treatment of diabetes as well as osteoporosis prevention are vital for this group of patients.

show abstract

“…One short study revealed that teriparatide did not affect glucose metabolism after 6 mo of treatment[ 144 ]. However, another study showed that after 6 mo of treatment with teriparatide (20 μg/d) fasting glucose and Homeostatic Model Assessment for IR index increased in postmenopausal women[ 145 ].…”

Section: Comprehensive Management Of Fracture Risk In Patients With Diabetesmentioning

confidence: 99%

Critical review of bone health, fracture risk and management of bone fragility in diabetes mellitus

Palui

Pramanik

Mondal

et al. 2021

WJD

View full text Add to dashboard Cite

The risk of fracture is increased in both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). However, in contrast to the former, patients with T2DM usually possess higher bone mineral density. Thus, there is a considerable difference in the pathophysiological basis of poor bone health between the two types of diabetes. Impaired bone strength due to poor bone microarchitecture and low bone turnover along with increased risk of fall are among the major factors behind elevated fracture risk. Moreover, some antidiabetic medications further enhance the fragility of the bone. On the other hand, antiosteoporosis medications can affect the glucose homeostasis in these patients. It is also difficult to predict the fracture risk in these patients because conventional tools such as bone mineral density and Fracture Risk Assessment Tool score assessment can underestimate the risk. Evidence-based recommendations for risk evaluation and management of poor bone health in diabetes are sparse in the literature. With the advancement in imaging technology, newer modalities are available to evaluate the bone quality and risk assessment in patients with diabetes. The purpose of this review is to explore the pathophysiology behind poor bone health in diabetic patients. Approach to the fracture risk evaluation in both T1DM and T2DM as well as the pragmatic use and efficacy of the available treatment options have been discussed in depth.

show abstract

Effect of teriparatide treatment on endothelial function, glucose metabolism and inflammation markers in patients with postmenopausal osteoporosis

Cited by 15 publications

References 33 publications

Bone Matrix Levels of Dickkopf and Sclerostin are Positively Correlated with Bone Mass and Strength in Postmenopausal Osteoporosis

Bone Matrix Levels of Dickkopf and Sclerostin are Positively Correlated with Bone Mass and Strength in Postmenopausal Osteoporosis

Treatment of Diabetes and Osteoporosis—A Reciprocal Risk?

Critical review of bone health, fracture risk and management of bone fragility in diabetes mellitus

Contact Info

Product

Resources

About